SS Innovations International, Inc. reported fourth‑quarter 2025 revenue of $14.5 million, an increase of 79.1% from $8.1 million in Q4 2024, and a net loss of $2.5 million, or $(0.01) per diluted share. Full‑year 2025 revenue reached $42.5 million, up 105.7% from $20.6 million in 2024, while the company posted a net loss of $12.1 million, or $(0.06) per diluted share.
The revenue growth was driven by a 119.1% rise in SSi Mantra system installations and an 81.8% increase in installations during the quarter, reflecting strong demand for the company’s cost‑efficient robotic platform. The company’s installation and procedure volumes continue to accelerate, supporting the top‑line expansion.
Gross margin for the full year expanded to 46.0% from 40.9% in 2024, while the quarter’s margin of 43.9% fell from 48.9% in Q4 2024. The compression in the quarter was largely due to higher investment in research and development and a shift toward higher‑volume, lower‑margin service contracts, offset by the margin lift from the growing SSi Mantra sales.
On March 6 2026, SS Innovations completed a private placement of common stock that raised $18.6 million in gross proceeds. The proceeds are earmarked for working capital and global expansion, including preparation for entry into the United States and European Union markets. Insider buying by the CEO and directors on the same day, totaling approximately $5.2 million, signaled management confidence in the company’s growth trajectory.
"In the fourth quarter of 2025, we achieved strong growth in SSi Mantra installations, procedures and revenues, capping off a successful year for SS Innovations," said Dr. Sudhir Srivastava, Chairman and CEO. "The net proceeds from this financing will advance our growth initiatives in India and other existing global markets, while supporting our preparation for entry into the United States and European Union markets." "We anticipate that the U.S. Food and Drug Administration will complete its review of our 510(k) premarket notification for our SSi Mantra surgical robotic system by mid‑2026," he added. "We also continue along the pathway towards a European Union CE marking certification for the SSi Mantra, which we believe we can also obtain in 2026." "Insider participation in this financing reflects our strong confidence in SS Innovations' future and our commitment to democratizing access to world‑class surgical robotic care," the CEO added.
The market reaction was driven primarily by the insider buying activity and the successful private placement, which together underscored management’s confidence and the company’s strengthened capital position. The announcement of the FDA 510(k) review timeline and the pursuit of CE marking further reinforced expectations of future revenue growth as the company expands into new regulatory markets.
The content on EveryTicker is for informational purposes only and should not be construed as financial or investment advice. We are not financial advisors. Consult with a qualified professional before making any investment decisions. Any actions you take based on information from this site are solely at your own risk.